Lilly hands Elan manufacturing first major contract

Related tags Eli lilly and company Chief executive officer Executive officer Élan

Ireland's Elan has signed its first major contract manufacturing
and supply agreement in a development that reinforces its
credentials as a player in the outsourcing sector.

Financial terms of the deal were not disclosed and neither was the volume of production involved.

The agreement is with US drug major Eli Lilly, and will see Elan supplement Lilly's in-house manufacturing of duloxetine hydrochloride capsules beginning in mid-2005. The drug is marketed under the trade name Cymbalta as an antidepressant and as Yentreve (and by Boehringer Ingelheim as Aridaim) for the treatment of urinary incontinence.

Kelly Martin, Elan's president and chief executive officer, said: "This agreement represents a significant milestone for Elan as it is our first large-scale manufacturing agreement with a leading pharmaceutical company."

Duloxetine capsules will be produced at Elan's US Food and Drug Administration (FDA)/European Medicines Agency (EMEA)-approved Athlone site, which the company expanded last year at a cost of $178 million.

Meanwhile, Lilly has been expanding its own capacity to make duloxetine, announcing earlier this month an investment of €41.6 million in its Spanish manufacturing plant in Alcobendas, near Madrid, to produce the drug.

Analysts have high expectations for the drug, which is tipped to make sales of more than $2 billion (€1.66bn) at peak.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...